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1. Introduction
The extensive genetic diversity of the human immunodeficiency virus (HIV) poses a
formidable challenge to the development of an efficacious HIV vaccine (HVTN, 2006).
An HIV vaccine may prevent infections with viruses genetically similar to a virus repre-
sented in the vaccine, but fail against genetically dissimilar viruses. Data on the amino
acid sequences of the viruses that infect participants in preventive HIV vaccine efficacy
trials can be used to assess how the efficacy of the candidate vaccine depends on ge-
netic mismatching of exposing viruses. “Sieve analysis” methods have been developed
for this purpose, which are based on comparing the genetic distances (to the vaccine
sequence) of the sequences of infected vaccine recipients to the genetic distances of the
sequences of infected placebo recipients (Gilbert, Self, and Ashby, 1998). Previously
developed sieve analysis methods considered “low dimensional” cases in which viruses
are classified exhaustively by a small number of K genotypes/phenotypes, or are or-
dered by K scalar summary measures of distance. However, there are many thousands
of distinct HIV genotypes as defined by amino acid sequence. Consequently, the prob-
lem of identifying sequence patterns that differentiate between the two sets of infecting
viruses is a high dimensional data problem, in which the number of variables (sequence
positions) exceeds the number of observations (infected subjects). In a typical efficacy
trial, 100-400 subjects are infected and 500-3300 sequence positions are studied.
The dataset available from an efficacy trial that we consider is the aligned HIV
amino acid sequences sampled from infected vaccine and placebo recipients, with one
sequence per subject. We develop techniques for “genome scanning”, whereby a sliding
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window is used within which the amino acids in the two aligned sequence sets are
compared to the amino acid at the corresponding position in the reference sequence,
and the goal is to identify “signature positions” (see Figure 1). A signature position
is a position at which vaccinee sequences exhibit significantly greater divergence from
the reference amino acid than placebo sequences. Identifying a signature position may
suggest that amino acid changes in that position were required in order for HIV to
elude the vaccine-induced immune response and hence establish infection. For example,
certain N-linked glycosylation positions in the glycoprotein 120 (gp120) region of HIV
appear critically important for HIV to evade neutralization (Wei et al., 2003), and
the vaccine may fail to protect against viruses with certain mutant amino acids in
these positions. Finding a signature position could imply the necessity to add multiple
different antigens to the vaccine, with amino acid sequences that match contemporary
circulating viral strains, in order for the vaccine to protect broadly. Therefore the
results of genome scanning analyses can guide the design of new vaccines.
Consideration of one of the most commonly used methods for studying HIV sig-
nature positions, VESPA (Korber and Myers, 1992; http:hiv-web.lanl.govcontenthiv-
dbmainpage.html), demonstrates the need for new methodology. VESPA is purely
descriptive- it compares the frequency of the most common amino acid at positions
between two sequence sets, without weighting the particular amino acids involved, and
without using a probabilistic framework to control error rates. Our approach to the
scanning analysis divides into three parts:
1. For each position, construct a two-sample test statistic that compares amino acid
divergences or frequencies between the two groups;
2. Approximate the null distribution of the test statistics across the set of studied
amino acid positions, and obtain position-specific p-values;
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3. Apply a multiple testing adjustment procedure to the set of unadjusted p-values
to infer the set of signature positions, controlling for a false positive rate.
For 1., various statistics for evaluating sequence distances have recently been pro-
posed, based on standardized Euclidean distance and Kullback-Leibler discrepency
(Wu, Hsieh, and Li, 2001), and Mahalanobis distance (Kowalski, Pagano, and DeGrut-
tola, 2002). These metrics/discrepencies were developed in different contexts than
genome scanning analysis, so their relative utility for our application is unknown. Ac-
cordingly we develop and compare test statistics based on all three of these approaches,
generalized to incorporate weight functions that can make amino acid distances more
immunologically relevant and thus hopefully more predictive of vaccine efficacy.
The test statistics evaluate the null hypothesis that the amino acids in the two sets
of sequences have equal distributions of divergence to the reference amino acid. We
also construct versions of the statistics that test for equal frequency distributions of
amino acids at the position, irrespective of a reference amino acid.
For 2., we consider two approaches to approximating the null distributions. The first
is a standard permutation procedure that only uses information at individual positions.
The second approach, following Pan (2003), pools information across all positions and
estimates the null distributions of the test statistics directly and nonparametrically.
Efron (2004) also pointed out that a large number of tests presents an opportunity to
estimate the null distribution directly as a novel approach to coping with high dimen-
sional data. We apply both approaches to obtain unadjusted p-values for each of the
positions, which are then subjected to a multiple comparisons adjustment procedure.
For 3., we apply the modified Bonferroni method developed by Tarone (1990) to
control the family-wise type I error rate (FWER) across positions, as well as a recent
modification of the original false discovery rate (FDR) procedure that also exploits the
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discrete characteristics of the genetic data to increase power (Gilbert, 2005).
This article is organized as follows. Section 2 develops three new test statistics
for identifying signature positions. Section 3 describes the procedures for obtaining
p-values and summarizes the multiple comparisons techniques employed, and describes
two slightly modified test statistics that are suitable for use with the nonparametric
estimation method for deriving p-values. Section 4 compares the performance of the
various methods in numerical studies, Section 5 presents an example from the first HIV
vaccine efficacy trial, and Section 6 gives concluding remarks.
2. Genome Scanning Methods for Identifying Signature Positions
2.1 Preliminaries
The data available for genome scanning analysis are n1 +n2 +1 aligned amino acid
sequences, one from each infected trial participant (n1 vaccine arm; n2 placebo arm),
plus a reference sequence represented in the vaccine construct, all of which are p amino
acids long. The amino acids compose HIV proteins, and the analysis considers the set
of positions that constitute the HIV proteins expressed by the tested vaccine. Current
vaccine candidates express proteins spanning p ∼ 500− 3300 positions (HVTN, 2006).
For the ith position and the jth sequence in the kth group, k = 1, 2, we define a
vector of indicators to represent the 20 amino acids possible at position i, including
the possibility of a gap which may have arisen in the alignment. Specifically, let
Ykj(i) = (Ykj(i, 1), · · · , Ykj(i, 21))
′, where Ykj(i, a) is 1 if amino acid a is at position
i and 0 otherwise, a = 1, · · · , 20 (a = 1 represents A, Alanine; a = 2 represents C,
Cysteine; and so on in alphabetical order), and a = 21 represents a gap. Similarly
define Yr(i) = (Yr(i, 1), · · · , Yr(i, 21))
′ for the reference sequence, and let r(i) denote
the amino acid at position i in the reference sequence. The vector Ykj(i) is a 21-nomial
random variable with response probability vector pk(i) = (pk(i, 1), · · · , pk(i, 21))
′. The
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MLE of pk(i) is p̂k(i) = (Y¯k(i, 1), · · · , Y¯k(i, 21))
′, where Y¯k(i, a) = n
−1
k
∑nk
j=1 Ykj(i, a).
The biological significance of a difference in two amino acids at a position depends
on the particular amino acids being compared (e.g., T vs Y). There is a vast literature
on how to weight the 20× 19 = 380 different amino acid mismatches, by physico-
chemical or evolutionary properties, and our methods incorporate a weight matrix to
reflect such information. Specifically, let M be a 21 × 21 matrix with nonnegative
entries, with (a, a′)th element the weight/score summarizing dissimilarity of amino
acids a and a′. For example, the nondiagonal entries of M could be taken to be those
from a hydrophobicity/biochemical scoring matrix (George, Barker, and Hunt, 1990).
The distance between the amino acid at position i in the jth sequence of group k to
the amino acid at position i in the reference sequence, r(i), is the appropriate element
of M , computed as dkj(i) = Ykj(i)
′MYr(i). The simplest matrix M = J − I, with J
the 21 by 21 matrix of ones and I the identity matrix; with this matrix dkj(i) is one if
the two amino acids under comparison are different and is zero if they are the same.
2.2 Two-sample Test Statistics
For each position i, test statistics are developed to evaluate H0(i) : p1(i) = p2(i)
versus H1(i) : p1(i) 6= p2(i). The choice of weight matrix M determines whether the
procedures test for differential amino acid divergence from the reference amino acid
or for differential amino acid frequencies, irrespective of any reference. Zeros on the
diagonal of M yields tests of the former type, and M = J of the latter type.
For position i, set
v̂2(i, a) = M(a, r(i))
[
(n1 − 1)
(n− 2)
V̂ ar(p̂11(i, a) +
(n2 − 1)
(n− 2)
V̂ ar(p̂21(i, a))
]
M(a, r(i)).
Let p∗(i) be the number of nonzero components in v̂2(i, a) minus one, and define
ZE(i) = CE(i)
21∑
a=1
(M(a, r(i)) [p̂1(i, a)− p̂2(i, a)])
2
{v̂(i, a) + λ1}2
I(v̂(i, a) > 0), (1)
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where CE(i) = [(n − p
∗(i) − 1)/(p∗(i)(n − 2))] × [(n1 − 1)(n2 − 1)/(n − 2)] and λ1 is
a nonnegative constant. Note that M(a, r(i)) [p̂1(i, a)− p̂2(i, a)] = d¯1(i, a) − d¯2(i, a).
The constant λ1 is added to the denominator of ZE(i) to stabilize the statistics, which
can be large due to small v̂(i, a). Efron et al. (2001), Tusher et al. (2001), and Guo et
al. (2003) suggested adding a small positive constant to two-sample statistics in high
dimensional data microarray applications, and Lo¨nnstedt and Speed (2002) showed
that the modified statistics perform better than the usual t-statistic. Following the
approach of Tusher et al. (2001), we choose λ1 to minimize the coefficient of variation
of {ZE(i) : i = 1, · · · , p}. An alternative approach would pick λ1 as the 90
th percentile
of {v̂(i, a) : i = 1, · · · , p; a = 1, · · · , 21} (Efron et al., 2001).
For the second test statistic, Mahalanobis’ D2 statistic for position i is given by
D2(i) = (p̂1(i)− p̂2(i))
′diag(MYr(i))Ŝ
−
λ2
(i)diag(MYr(i))(p̂1(i)− p̂2(i)),
where Ŝ−λ2(i) is the Moore-Penrose generalized inverse of Ŝλ2(i) ≡ Ŝ(i)+λ2diag(1nz(i)),
with Ŝ(i) = [(n1−1)Ŝ1(i)+(n2−1)Ŝ2(i)]/(n−2) and λ2 a nonnegative constant. Here
Ŝk(i) = diag(p̂k(i)) − p̂k(i)p̂k(i)
′ is the multinomial MLE of Sk(i) = diag(pk(i)) −
pk(i)pk(i)
′, and 1nz(i) is the 21-vector of indicators of whether the ath row of Ŝ(i) is
not the zero vector, a = 1, · · · , 21. S−λ2(i) can be computed by calculating the Moore-
Penrose inverse of the submatrix of Ŝλ2(i) formed by removing the zero-vector rows
and columns (corresponding to amino acids never present or always present at position
i), and then expanding the generalized inverse to a 21× 21 matrix by re-inserting the
zero-vector rows and columns. When M = J and λ2 = 0, D
2(i) is the Mahalanobis
statistic that has been used extensively (cf., Rao and Chakraborty, 1991).
The second test statistic, ZM(i), is defined by
ZM(i) =
(n− p∗(i)− 1)
p∗(i)× (n− 2)
n1n2
n
D2(i).
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Similarly to ZE(i), the diagonal matrix λ2diag(1nz(i)) is added to Ŝ(i) to stabilize
ZM(i). The constant λ2 is selected to minimize the coefficient of variation of the test
statistic via the algorithm of Guo et al. (2003, page 1630). A potential advantage
of ZM(i) compared to ZE(i) is that it accounts for the correlation structure of the
multinomial response vectors, which could possibly increase statistical power.
The third statistic is based on the Kullback-Leibler discrepency, which is relatively
easy to compute. For position i, let ZKL(i) =
21∑
a=1
M(a, r(i))p̂1(i, a)log
{
I(p̂2(i, a) > 0)
p̂1(i, a)
p̂2(i, a)
+ I(p̂2(i, a) = 0)
(p̂1(i, a) + n
−1
1 )
n2
}
. (2)
Wu, Hsieh, and Li (2001) suggested placing the indicator I(p̂2(i, a) > 0) in the Kullback-
Leibler discrepency, which for our problem prevents ZKL(i) from taking infinite value.
3. Judging Statistical Significance
3.1 Permutation-based Unadjusted p-values
To judge statistical significance of the p tests, first nominal (unadjusted) position-
wise p-values are computed. Since analytic p-values based on limiting distributions are
not available for the test statistics (except Euclidean and Mahalanobis with λ1 = λ2 =
0), and parametric distributional assumptions may be unreliable given the underlying
discreteness of the sequence data, we use a permutation procedure to determine p-
values. Specifically, B data sets, each of n = n1 + n2 sequences, are generated by
independently permuting the group membership labels of the whole sequences. The
p-value for position i is calculated as the fraction of the test statistics computed using
the B permuted datasets that equal or exceed the value of the original test statistic.
3.2 Nonparametric Estimated Null Distribution-based Unadjusted p-values
In the second (pooling) approach to computing position-specific p-values, slightly
modified versions of ZE(i) and ZM(i) are needed, as described below. These modi-
fied statistics advantageously incorporate a position-specific weight w1(i), i = 1, · · · , p,
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which can be used to reflect biological information. For example, positions could be
weighted by their conservancy (a position is relatively conserved if most sequences
contain the same amino acid at the position), since conserved positions may be more
functionally or structurally important than variable positions. For exploratory anal-
yses, where the aim is to generate hypotheses about positions that warrant further
biological examination, equal weights w1(i) = 1 may be recommended, because they
prevent subjective biases from influencing the results, and they may be agreed upon
broadly across investigators. For these reasons equal weights are used in the Example.
To develop the pooling approach, we follow Pan’s (2003) clever idea for how to
directly nonparametrically estimate the null distribution of hundreds of t-statistics.
Assume that under all H0(i)’s, the test statistics of interest Z(i) have the same distri-
bution for i = 1, · · · , p. For each group of sequences separately, randomly permute the
sequences into two (almost) equally-sized pieces, labeled sets Jk1, Jk2, k = 1, 2. Define
nk2 = nk1 if nk = 2nk1 and nk2 = 2nk1 + 1 otherwise, k = 1, 2. Modify (slightly) the
test statistic ZE(i) of (1) to Z
split
E (i) = w1(i)CE(i)×
21∑
a=1
{M(a, r(i)) [(p̂11(i, a) + p̂12(i, a))/2− (p̂21(i, a) + p̂22(i, a))/2]}
2
{v̂(i, a) + λ1}
2 I(v̂(i, a) > 0),
where p̂k1(i, a) = n
−1
k1
∑nk
j=1 Ykj(i, a)I(j ∈ Jk1) averages the Ykj(·) in the first permuted
half of sample k and p̂k2(i, a) averages the Ykj(·) in the second permuted half. The
statistic ZsplitE (i) approximately equals ZE(i), and motivates a statistic that estimates
its null distribution: zsplitE (i) = w1(i)CE(i)×
21∑
a=1
{M(a, r(i)) [(p̂11(i, a)− p̂12(i, a))/2 + (p̂21(i, a)− p̂22(i, a))/2]}
2
{v̂(i, a) + λ1}
2 I(v̂(i, a) > 0).
Because the numerator of zsplitE (i) is the sum of within-sample differences, its mean is
zero. Furthermore, the denominators of ZsplitE (i) and z
split
E (i) are the same, and thus
zsplitE (i) can be expected to approximate the null distribution of Z
split
E (i).
9
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To obtain p-values, once ZsplitE (i) is computed, each group of sequences is again
separately randomly permuted into two halves, and zsplitE (i) is computed. Based on B
separate permutations z
split(b)
E (i) is computed B times, b = 1, · · · , B. For position i the
p-value is then pi = Ni/(B×p), where Ni is the number of the test statistics z
split(b)
E (i
′)
that equal or exceed ZsplitE (i), pooling over i
′ = 1, · · · , p and b = 1, · · · , B.
We use a very similar approach to estimate the null distribution of a slightly mod-
ified version of ZM(i), Z
split
M (i), defined as
ZsplitM (i) = w1(i)
(n− p∗(i)− 1)
p∗(i)× (n− 2)
n1n2
n
D2split(i), (3)
where D2split(i) is the same as D2(i) with p̂1(i)−p̂2(i) replaced with (p̂11(i)+p̂12(i))/2−
(p̂21(i)+p̂22(i))/2. The null distribution of Z
split
M (i) can be estimated via z
split
M (i) defined
as in (3) with (p̂11(i)+ p̂12(i))/2− (p̂21(i)+ p̂22(i))/2 replaced with (p̂11(i)− p̂12(i))/2+
(p̂21(i)− p̂22(i))/2. P -values are then obtained in the same way as for Z
split
E (i).
Note that the position weights w1(i) affect the p-values because the pooling method
is used; weights placed in front of the non-split statistics described in Section 2 would
not affect the permutation-based p-values, because they are computed marginally.
3.3 Multiple Hypothesis Testing Adjustment
Given the set of p-values, we consider four multiple comparisons adjustment pro-
cedures to determine the set of significant signature positions: standard Bonferroni,
Tarone’s (1990) modified Bonferroni method for discrete data, standard FDR (Ben-
jamini and Hochberg, 1995), and Tarone-modified FDR for discrete data, which we
refer to as “Tarone FDR” (Gilbert, 2005). We sketch the latter procedure in two steps:
First, compute the integer K and the subset of indices RK among the p hypotheses as
described by Tarone (1990); Second, perform Benjamini and Hochberg’s (1995) FDR
procedure at level α on the subset of hypotheses RK . To define K and RK , for each
k = 1, · · · , p, let m(k) be the number of the p positions for which α∗i < α/k, where α
∗
i
10
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is the minimum achievable significance level for the test for the ith position, computed
based on data pooled over the two groups. Then K is the smallest value of k such
that m(k) ≤ k, and RK is the set of indices satisyfing α
∗
l < α/K. Because K and RK
are calculated based only on information pooled over the vaccine and placebo groups,
this procedure controls the FDR at level α. Due to the complexity of computing the
α∗i for each of the newly proposed test statistics, for the Simulations and Example the
α∗i were computed based on Fisher’s exact test.
4. Simulation Study
4.1 Background
The simulation study is designed based on data from the first HIV vaccine efficacy
trial (Flynn et al., 2005). Healthy HIV uninfected volunteers were randomized to
receive vaccine (Nv = 3598) or placebo (Np = 1805) and were tested for HIV infection
every 6 months for 36 months. The vaccine was a recombinant envelope gp120 subunit
vaccine, and was designed to prevent acquisition of HIV by inducing antibodies that
could bind to neutralizing epitopes on HIV gp120 and prevent entry of HIV into host
cells. The vaccine did not prevent HIV infection, with a similar rate of infection in
the vaccine (241/3598 = 6.7%) and placebo (127/1805 = 7.0%) arms. For 336 of the
368 infected participants three HIV isolates were sampled at the time of HIV infection
detection, and the amino acid sequence of gp120 was determined by direct translation
of the DNA sequence for each isolate. Sequences from the same individual were highly
similar, and we considered one randomly selected sequence from each subject. The
336 gp120 sequences were aligned together with the two gp120 sequences that were
represented in the vaccine construct, named MN and GNE8. Since GNE8 was sampled
more recently and was closer genetically to the infecting sequences, it was used as the
reference sequence in all analyses. There are n1 = 217 vaccine group sequences and
11
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n2 = 119 placebo group sequences, each of length p = 581.
For each of the five testing procedures developed above, plus Fisher’s exact test
for comparison, simulations were carried out to address the following questions: 1)
What is the impact of the proportion of positions with a true alternative hypothesis
on the performance of the procedures? 2) How much power is there to detect signature
positions for vaccine efficacy trials of different sizes? 3) How do the position weights
w1(i) influence size and power of the split test statistics? 4) What is the impact of
the constants λ1 and λ2 in the performance of the Euclidean- and Mahalanobis-based
procedures? To address these questions, gp120 sequences for the infected placebo group
were simulated by randomly sampling with replacement n2 = 90 or 180 whole sequences
from the 336 sequences. Assuming an overall vaccine efficacy of 50%, sequences for
the infected vaccine group were generated by sampling with replacement n1 = 45 or
90 whole sequences from the 336 sequences. To create the alternative hypothesis at
a given position i, we used the HIV-specific PAM matrix developed by Nickle et al.
(2005) to induce stochastic evolution of the amino acids at i in the vaccinee sequences.
Each nondiagonal entry of the PAM matrix corresponds to two different amino acids,
and specifies the probability that either of the amino acids mutates into the other one
during a certain amount of evolutionary time. We used the PAM−25 matrix, which
specifies a total of 25 amino acid interchanges per 100 positions.
Question 1) was addressed by setting 1%, 10% or 25% of the positions to have true
alternatives, which amounts to 6, 58, or 145 of the 581 positions. We selected the posi-
tions based on previous studies supporting that 39 of the 581 positions are important
for HIV neutralization or CD4 co-receptor binding. Specifically, Wyatt et al. (1998)
identified the CD4-binding positions 88, 113, 117, 256, 257, 262, 266, 368, 370, 384,
421, 427, 457, 470, 474, 475, 477, 482, 483, 484, the CD4-induced epitope positions 88,
12
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117, 121, 207, 256, 257, 262, 370, 381, 382, 419, 420, 421, 422, 423, 427, 435, 438, 475,
and positions 295, 297, 334, 386, 392, 397, which constitute a neutralization epitope
defined by the monoclonal antibody 2G12. The positions, here and in the Example, are
numbered using the standard HXB2 strain numbering system (Kuiken et al., 2002). In
addition, Wei et al. (2003) identified three positions at which amino acid changes can
sterically inhibit the accessibility of principal neutralizing epitopes on the virus surface:
245, 274, 309. These comprise 39 unique positions. For the 6 alternative positions,
we selected the positions constituting the monoclonal antibody 2G12 neutralization
epitope (295, 297, 334, 386, 392, 397); for the 58 alternative positions we selected the
39 key positions listed above plus 19 randomly sampled positions; and for the 145 alter-
native positions we used these 58 positions plus 87 more randomly sampled positions.
Question 2) was addressed by repeating the simulation experiment for small (n1/n2 =
45/90 infections) and large (n1/n2 = 90/180 infections) efficacy trials. Question 3) was
addressed by running simulations with w1(i) = I(H0(i) true) + cI(H0(i) false) with
c set as 2.0 or 0.5, which evaluate the split test statistics when the true alternative
hypotheses are upweighted 2-fold (correctly incorporating prior knowledge) or down-
weighted 2-fold (incorrectly incorporating prior knowledge), respectively. Question 4)
was addressed by repeating the simulations with λ1 and λ2 set to zero.
Amino acid substitutions were weighted equally, by setting M = J − I. Except for
results reported at the end of Section 4.3, positions in the split statistics were weighted
equally (w1(i) = 1). Tests were carried out at 2-sided level α = 0.05, using 250
permutations to approximate p-values. Empirical false positive rates, false discovery
rates, and powers of the testing procedures were computed.
4.3 Simulation Results
Figure 2 shows the estimated false positive rates and FDRs using the Tarone Bon-
13
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ferroni and Tarone FDR multiple testing adjustment methods, respectively. The tests
based on ZE(i), ZM(i), Z
split
E (i), Z
split
M (i) use λ1 = λ2 = 0, due to their superior perfor-
mance as described below. All of the test procedures are conservative under family-wise
error adjustment (left panels). Under FDR adjustment, when 10% or 25% of the null
hypotheses are false, all of the procedures except the two Mahalanobis-based tests con-
trol the FDR below 0.05 within 2 Monte Carlo standard errors. When only 1% of the
null hypotheses are false, all of the proposed procedures have estimated FDRs higher
than 0.05. This occurs because in many simulation runs the null hypothesis was only
rejected at 1 or 2 positions, in which case a single false rejection makes the FDR very
high (e.g., 0.5 for 2 total rejections). This suggests that the FDR method should not
be used unless the Tarone Bonferroni method rejects at least one null hypothesis. The
tests based on ZE(i), ZM(i), Z
split
E (i), Z
split
M (i) with λ1 > 0 and λ2 > 0 had very similar
false positive and FDR rates.
Figure 3 shows the estimated powers of the procedures. We make several observa-
tions. First, the Kullback-Leibler and standardized Euclidean statistics are consistently
most powerful. Fisher’s exact statistic is third most powerful, with ZsplitE (i) providing
similar power at the larger sample size under FDR adjustment. Second, the statis-
tics that use pooling are generally less powerful than their non-pooled counterparts,
moreso for lower fractions of false null hypotheses. It appears that the pooling methods
perform best when many alternative hypotheses are true (consistent with Pan, 2003).
Third, the tests based on ZM(i) and Z
split
M (i) consistently have the lowest power.
To explain the poor performance of the Mahalanobis-based statistics, note that the
rank of the estimated covariance matrix Ŝ(i) is often fairly high, which occurs because
the gp120 region is highly variable. Consequently there are dozens of covariance terms
to estimate, but the sample size is quite limited for doing so. Therefore, we conjecture
14
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that the noise in covariance estimation is causing the poor performance. To support
this conjecture, we repeated the simulations with all covariance estimates set to zero,
in which case the Mahalanobis-based test statistics are very similar to the Euclidean-
based statistics. With this modification these two approaches performed similarly.
Fourth, the tests based on ZE(i) and Z
split
E (i) with λ1 = 0 are consistently more
powerful than the corresponding tests with λ1 > 0 (not shown in figures). For example,
for the smaller sample size and FWER adjustment, power of the ZE(i) tests with λ1 = 0
is 0.45, 0.73, and 0.63 for 1%, 10%, and 25% of H0(i)’s false, respectively, compared to
0.20, 0.59, and 0.51 for the ZE(i) tests with λ1 > 0. Similarly, for the larger sample size
and FWER adjustment, power of the ZsplitE (i) tests with λ1 = 0 is 0.12, 0.42, and 0.27
for 1%, 10%, and 25% of H0(i)’s false, compared to 0.01, 0.27, and 0.18 for the Z
split
E (i)
tests with λ1 > 0. This result can be explained by the fact that the sum
∑21
a=1 in ZE(i)
is restricted to contrasts p̂1(i, a)− p̂2(i, a) for which the estimated variance is positive,
which prevents the denominator from being very near 0. Similarly for ZsplitE (i).
Fifth, when 1% of null hypotheses are false, the Kullback-Leibler and standardized
Euclidean statistics have much greater power than the other methods. Therefore these
methods are recommended for low signal-to-noise applications.
Sixth, the split statistics with true alternative positions upweighted have lower
false positive/discovery rates and greater power than the equal-weighted methods; for
example with m1/m2 = 45/90 and 10% of the alternative hypotheses true, the FDR of
the ZsplitE (i) tests with λ1 = 0 is 0.0, compared to 0.032 for the unweighted tests, and
power is 0.26 (0.64) under Tarone Bonferroni (Tarone FDR) compared to 0.23 (0.56)
for the unweighted tests. On the other hand when the true alternative positions were
downweighted, the opposite results attained: the ZsplitE (i) tests with λ1 = 0 give inflated
FDR = 0.078 and low power 0.10 (0.21). These results provide preliminary “proof-
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of-principle” that correct upweighting of positions can improve size and power of the
tests based on ZsplitE (i), but incorrect weighting can erode performance. This suggests
that weighting to incorporate biological knowledge should be done with caution.
5. Example
The matrix M was taken as J−I, or as the HIV-specific PAM−250 matrix of Nickle
et al. (2005), modified to have zeros on the diagonal and a vector of zeros added to the
21st row and 21st column. This matrix was computed based on thousands of observed
among-patient mutations in HIV sequences. Because the previously available amino
acid substitution matrices were built using organisms other than HIV, this PAM may
yield more accurate rates of HIV amino acid interchanges. Using this PAM to weight
amino acid mismatches may increase biological relevance.
With w1(·) = 1, M = J − I, and 10,000 permutations, Figure 4 shows the -log10-
transformed unadjusted p-values based on the six test statistics (setting λ1 = λ2 = 0)
for the 350 informative positions (i.e., those with enough diversity to possibly reject
H0(i) using the Tarone Bonferroni procedure), and Figure 5 shows histograms of the
test statistics. As indicated by the horizontal lines in Figure 4, after multiplicity ad-
justment the null hypothesis is not rejected for any positions by any of the tests, except
that ZsplitM (i) rejected one hypothesis (for position 435). The analysis was repeated for
the subset of the 39 biologically-key positions described in the Simulations. Again only
ZsplitM (435) rejected, which we expect to be a false positive result due to the lack of
corroboration by the other tests. Similar null results were obtained when M was set
as the modified PAM matrix. The result of no signature positions can be explained by
the inability of the tested vaccine to prevent HIV infection. If the vaccine has no effect
on susceptibility to acquiring HIV, then the distribution of infecting sequences should
be identical in the vaccine and placebo groups.
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Because there was a suggestion of possible partial vaccine efficacy in non-white
participants (infection rates 5.0% and 9.4% in the vaccine and placebo groups, unad-
justed p = 0.012) and in participants with high self-reported risk behavior at baseline
(infection rates 20.3% and 29.2%, unadjusted p = 0.032) (Flynn et al., 2005), the scan-
ning analyses were repeated in these subgroups. No significant signatures were found,
supporting that the apparent efficacy in these subgroups may not have been real.
To illustrate an application with significant signature positions, 251 gp160 subtype
B HIV-1 sequences were downloaded from the Los Alamos HIV Sequence Database
(Kuiken et al., 2002), 61 known to be CXCR4 co-receptor utilizing viruses and 192
known to be CCR5 co-receptor utilizing viruses. The sequences were multiply aligned,
with common length p = 857 amino acid positions. The procedures with M = J were
applied to the data, to test for positions with different amino acid frequency distri-
butions. Many significant signatures are found by all of the procedures; for example
at level α = 0.05 ZE(i) yields 25 (44) significant signature positions under Tarone
Bonferroni (Tarone FDR) adjustment, and ZKL(i) yields 26 (51) significant signature
positions. In comparison Fisher’s exact test provides only 10 (22) significant signatures,
demonstrating greater power of the new testing procedures.
6. Discussion
We developed and evaluated five new testing procedures for detecting signature po-
sitions that distinguish two groups of amino acid sequences. The Kullback-Leibler and
standardized Euclidean test statistic (with constant λ1 in the denominator set to 0)
were most powerful and are recommended. The efficiency of the Kullback-Leibler dis-
crepency likely derives from the fact that it is an expected log likelihood ratio, and has
optimality properties closely related to those of likelihood ratio tests, as has been widely
studied (Eguchi and Copas, 2002, provide a particularly clear discussion). A related
17
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standardized Euclidean statistic was also found to perform well by Wu et al. (2001),
and in our setting we conjecture that it provided greater power than the Mahalanobis-
based test because it standardizes only by the variance estimates, thereby avoiding the
noise introduced by estimating the entire covariance matrix nonparametrically.
An advantage of the methods developed here is that they incorporate a weight
matrix specifying dissimilarity values for all pairs of different amino acids, as well as
weights on amino acid positions. Therefore the techniques can flexibly incorporate
biological knowledge about sequences, and can be tailored to different applications.
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Figure Legends
Figure 1. Illustration of amino acid sequence data available for genome scanning
analysis, from 6 randomly selected HIV infected vaccine and placebo recipients in the
VaxGen trial, aligned together with the reference HIV vaccine sequence GNE8. Each
capital letter denotes an amino acid, which is a basic building block of proteins. A
sequence of contiguous amino acids constitutes a protein. A - denotes a gap that arose
in the alignment; gaps occur because the lengths of HIV sequences differ. The V3 loop
region within the HIV protein gp120 is shown, which consists of positions 297-328 of
gp160 using the HXB2 strain numbering system (Kuiken et al., 2002).
Figure 2. Based on the simulation study, panels (a) and (c) show average false positive
rates for the testing procedures (with λ1 = λ2 = 0) using the Tarone Bonferroni
multiple testing adjustment procedure, for n1/n2 = 45/90 infections and n1/n2 =
90/180 infections, respectively. Panels (b) and (d) show the corresponding average
false discovery rates for the Tarone FDR multiple testing adjustment procedure.
Figure 3. Based on the simulation study, panels (a) and (c) show average true pos-
itive rates (powers) for the testing procedures (with λ1 = λ2 = 0) using the Tarone
Bonferroni multiple testing adjustment procedure, for n1/n2 = 45/90 infections and
n1/n2 = 90/180 infections, respectively. Panels (b) and (d) show the corresponding
estimated powers for the Tarone FDR multiple testing adjustment procedure.
Figure 4. -log10 unadjusted p-values from the testing procedures (with λ1 = λ2 =
0), for the 350 informative positions among the p = 581 positions analyzed in the
VaxGen trial, with equal weighting of all amino acid mismatches and all positions.
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The horizontal lines represent cut-off levels of significance after adjustment for multiple
testing using four different multiple testing adjustment procedures.
Figure 5. Histograms of the test statistics for the 350 informative positions among
the p = 581 positions analyzed in the VaxGen trial, with equal weighting of all amino
acid mismatches and all positions.
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